DISCLOSURE; PATENT PROSECUTION. (a) Each of NeoGenesis and Immusol shall promptly disclose to the other in writing any Invention that might, under the applicable U.S. patent laws, be patentable and constitutes Program Intellectual Property. Such Program Intellectual Property will be added to ATTACHMENT B. Within forty five (45) days following the date of such disclosure regarding the existence of particular Program Intellectual Property that is jointly owned, the parties shall confer and mutually agree as to appropriate protection for such Program Intellectual Property, including a patent application, preparation, prosecution and maintenance strategy. Notwithstanding the provisions of this Section 4.3, neither party shall file any Program Patent Right relating to Program Intellectual Property that is jointly owned without the other party's prior written consent.
DISCLOSURE; PATENT PROSECUTION. (a) Each of NeoGenesis and OGS shall disclose to the other the conception or reduction to practice, or the discovery, development or making of any Program Intellectual Property; such Program Intellectual Property will be added to ATTACHMENT B (and ATTACHMENT D if applicable) and will be subject to the provisions of this Agreement. Within forty-five (45) days following the date of such disclosure regarding the existence of particular Program Intellectual Property that is either (i) solely owned by NeoGenesis, but only to the extent that such Program Intellectual Property relates to the structure of any of the Selected Compounds (during the period prior to designation pursuant to Section 2.6) or Designated Compounds; or (ii) jointly owned by the parties, the Steering Committee shall confer as to the appropriate protection (if any) for such Program Intellectual Property. With respect to the Program Intellectual Property described Section 3.3(a)(i), such determination shall be made having reference to the likelihood that seeking patent protection will adversely effect future filings by OGS with respect to new chemical entities based upon such Designated Compound (or such Selected Compounds if the period for designation has not then expired). In the event that the Steering Committee is unable to reach unanimous agreement on whether patent protection should be sought, the provisions of Section 2.5(d) shall not apply and the parties agree that the dispute shall be governed by the provisions of Section 9.1.
DISCLOSURE; PATENT PROSECUTION. (a) Each of NeoGenesis and CUSTOMER shall promptly disclose to the other knowledge of any Program Intellectual Property, described under clause (a) or (b) of the definition of Program Intellectual Property and will be subject to the provisions of this Agreement. Within forty-five (45) days following the date of such disclosure regarding the existence of particular Program Intellectual Property that is jointly owned, the parties shall confer as to appropriate protection for such Program Intellectual Property. Except as otherwise expressly provided herein, all other inventions and discoveries governed by this Agreement shall be owned based on inventorship, as inventorship is determined in accordance with United States patent law. Except as specifically provided under this Agreement, the transfer of physical possession and use of any technology by CUSTOMER or NeoGenesis, as the case may be, shall not be (nor be construed as) a license, sale, lease, offer to sell or lease, or other transfer of title of such technology to CUSTOMER or NeoGenesis, as the case may be.
DISCLOSURE; PATENT PROSECUTION. S&W will disclose to Stemline any Inventions resulting from the Research Program as soon as possible after creation and/or reduction to practice. Stemline shall have the sole right to file patent applications claiming or covering any S&W Know-How, S&W Materials or other information disclosed by S&W to Stemline hereunder (including under Section 2.01(b) and/or this Section 2.07(b)) or arising under the Research Program, using patent counsel of its choice. Stemline shall provide S&W with a draft of any said application(s) a reasonable period prior to filing. In this case, S&W shall have *** (***) days, extendable for an additional *** (***) days upon reasonable request by S&W, to provide Stemline with comments on any such patent application(s), such comments to be reasonably considered and not unreasonably denied by Stemline.
DISCLOSURE; PATENT PROSECUTION. (a) Each Licensee will disclose to Licensor’s Technical Liaison, (i) within a reasonable period of time, knowledge of any Improvement to the Licensor Technology or Selected Non-Ethanol Technology (as applicable to the Licensee) developed by such Licensee or (ii) when Licensee makes such Invention generally commercially available, knowledge of any Invention developed by such Licensee. Any such Improvement and the license rights granted under Section 7.1(b) to any such Invention will be deemed to be part of the Licensor Technology or Licensor Non-Ethanol Technology, as applicable and will be subject to the provisions of this Agreement applicable to the Licensor Technology or Licensor Non-Ethanol Technology (but excluding, in any case, for purposes of Section 9).
DISCLOSURE; PATENT PROSECUTION. (a) Each of NeoGenesis and Mitsubishi shall promptly disclose to the other knowledge of any Program Intellectual Property; such Program Intellectual Property will be added to ATTACHMENT B (and ATTACHMENT D if applicable) and will be subject to the provisions of this Agreement. Within forty-five (45) days following the date of such disclosure regarding the existence of particular Program Intellectual Property that is jointly owned, the parties shall confer as to appropriate protection for such Program Intellectual Property. Notwithstanding the provision of this Section 3.3, no party shall file, prosecute and maintain any Program Patent Right without the other party's prior written consent before the date specified in ATTACHMENT A for Mitsubishi's notice of Designated Compounds.
DISCLOSURE; PATENT PROSECUTION. (a) Each party shall promptly disclose in writing to the other party knowledge of any Program Intellectual Property developed in the course of the Program. Such Program Intellectual Property will be subject to the provisions of this Agreement. CryoCor hereby assigns or otherwise transfers to BSC any right, title or interest that CryoCor may have in the BSC Program Intellectual Property, and BSC and BSS hereby assign or otherwise transfers to CryoCor any right, title or interest that BSC or BSS may have in the CryoCor Program Intellectual Property
DISCLOSURE; PATENT PROSECUTION. (a) Each of CytoDyn and Vyera shall promptly disclose to the other in writing reasonably detailed written reports describing any Invention that might, under the applicable U.S. patent laws, be patentable and constitute an Invention.
DISCLOSURE; PATENT PROSECUTION. (a) Each of CBLI and GPI shall promptly and fully disclose to the other in writing reasonably detailed written reports describing any Know-How that might, under the applicable U.S. patent laws, be patentable and constitute Program Intellectual Property (whether or not Joint Program Intellectual Property), regardless of the place of invention of such Know-How. With respect to the Licensed Technology that does not fall under the foregoing sentence, CBLI shall promptly disclose to GPI any Licensed Technology that arises during the term of the Agreement after such time as CBLI has taken steps deemed reasonably necessary by CBLI in its sole discretion to protect such Licensed Technology that constitutes CBLI Patent Rights, and with respect to GPI Intellectual Property that does not fall under the foregoing sentence, GPI shall promptly disclose to CBLI any GPI Intellectual Property and GPI Patent Rights after such time as GPI has taken steps deemed reasonably necessary by GPI in its sole discretion to protect such GPI Intellectual Property and GPI Patent Rights and only if such GPI Intellectual Property and GPI Patent Rights are the subject of the license set forth in Section 2.1(e) at such time. Within forty-five (45) days following the date of disclosure regarding the existence of Program Intellectual Property, the parties shall mutually confirm the inventorship and ownership of the Program Intellectual Property in accordance with Section 2.2(b) and, in the case of the Joint Program Intellectual Property, the parties shall confer and mutually agree as to appropriate protection for such Joint Program Intellectual Property, including an application, preparation, prosecution and maintenance strategy. Notwithstanding the provisions of this Section 6.1(a), neither party shall file any Patent Right relating to Program Intellectual Property without prior written mutual confirmation of inventorship and ownership in accordance with the immediate previous sentence nor any Joint Patent Right relating to Joint Program Intellectual Property without the other party’s prior written consent (which shall not be unreasonably withheld, delayed or conditioned).
DISCLOSURE; PATENT PROSECUTION. (a) Each of NeoGenesis and Aventis shall promptly disclose to the other knowledge of any Invention that constitutes Program Intellectual Property; such Program Intellectual Property will be added to ATTACHMENT B (and ATTACHMENT D if applicable) and will be subject to the provisions of this Agreement. Within forty-five (45) days following the date of such disclosure regarding the existence of particular Program Intellectual Property that is jointly owned, the parties shall confer as to appropriate protection for such Program Intellectual Property. Notwithstanding the provision of this Section 3.3, no party shall file, prosecute and maintain any Program Patent Right without the other party's prior written consent before the date specified in Section 2.8 for Aventis' notice of Lead Compounds.
